Canaccord Genuity began coverage on shares of Turning Point Therapeutics (NASDAQ:TPTX) in a research report report published on Monday morning, Benzinga reports. The firm issued a buy rating and a $48.00 price target on the stock.
TPTX has been the subject of several other reports. Wells Fargo & Co assumed coverage on Turning Point Therapeutics in a research report on Monday. They set an outperform rating and a $53.00 target price for the company. Goldman Sachs Group assumed coverage on Turning Point Therapeutics in a research report on Monday. They set a buy rating and a $50.00 target price for the company. Six analysts have rated the stock with a buy rating, Turning Point Therapeutics presently has an average rating of Buy and a consensus target price of $47.17.
Turning Point Therapeutics stock opened at $30.26 on Monday. Turning Point Therapeutics has a 1 year low of $24.21 and a 1 year high of $38.00.
In other Turning Point Therapeutics news, CEO Athena Countouriotis acquired 12,000 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were acquired at an average price of $18.00 per share, for a total transaction of $216,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Brian Lee Baker acquired 2,800 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were acquired at an average price of $18.00 per share, for a total transaction of $50,400.00. The disclosure for this purchase can be found here. Insiders have bought a total of 774,800 shares of company stock valued at $13,946,400 over the last 90 days.
About Turning Point Therapeutics
Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Featured Story: How to track put option volume
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.